Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Lantheus Holdings, Inc.
LNTH
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $7.1B
$109.89
▲ +0.85%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$47.25 - $111.86
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 36.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary radiopharmaceutical manufacturing expertise and FDA-approved product portfolio
- Strategic partnerships with global healthcare leaders (GE Healthcare, Bayer, Regeneron) providing distribution and development advantages
- Specialized focus on high-barrier nuclear medicine and molecular imaging markets with limited competition
- Integrated diagnostic and therapeutic capabilities enabling precision medicine solutions
- Established relationships with radio pharmacies, hospitals, and integrated delivery networks
Bear Case
2 risks
- Low volatility (beta 0.0).
- Premium valuation to Large Cap Pharma peers
Growth
Stable outlook
Rising demand for precision oncology and personalized cancer diagnostics and treatment
Value
Premium valuation to Large Cap Pharma peers
Momentum
Hot
+43.2% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying LNTH right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 30, 2026
MAY 7, 2026
Reported EPS of $1.46 vs $1.25 consensus (+16.8% surprise). Revenue of $377.3M vs $354.5M expected (+6.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+16.8%
Next: Apr 30, 2026
Revenue trend · last 8Q
—
—
+10%
+1%
-4%
+1%
+4%
+1%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$394.1M
$378.7M
$391.1M
$372.8M
$378.0M
$384.0M
$406.8M
$377.3M
Margins · last 8Q
Gross
—
Operating
—
Profit
31.4%
Wall Street consensus
4 analysts · 75% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
75%
Hold
25%
Sell
0%
Median Price Target
$98.00
▼ -10.8% vs $109.89
Latest: Mizuho · $115.00 · May 27, 2026
3 analysts covering
vs Industry
How LNTH stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related